<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01489306</url>
  </required_header>
  <id_info>
    <org_study_id>MDT-637-CP-102</org_study_id>
    <nct_id>NCT01489306</nct_id>
  </id_info>
  <brief_title>A Trial to Assess the Safety, Tolerability and Pharmacokinetics of MDT-637 in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Inhaled MDT-637 Administered to Healthy Volunteers for 10 Days</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MicroDose Therapeutx, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MicroDose Therapeutx, Inc</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the tolerability and safety of a range of repeated&#xD;
      inhaled doses of MDT-637. This includes monitoring effects on pulmonary function and&#xD;
      determination of blood levels of MDT-637 following inhalation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of 3 escalating doses of MDT-637 dry powder inhalation in healthy volunteers</measure>
    <time_frame>Up to 48 days (including up to 28 days of screening period)</time_frame>
    <description>Safety measurements include Clinical Laboratory Evaluations, Pulmonary Function Tests (Spirometry), ECG, Vital Signs, Physical Examination and Assessment of Adverse Events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetics for MDT-637 dry powder inhalation</measure>
    <time_frame>Multiple plasma samples collected during the dosing period, upto 24 hr post last dose</time_frame>
    <description>Plasma Samples will be measured to determine MDT-637 pharmacokinetics</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Drug Safety</condition>
  <arm_group>
    <arm_group_label>MDT-637</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched Placebo Comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MDT-637</intervention_name>
    <description>Inhaled doses of MDT-637 over a 10 day period</description>
    <arm_group_label>MDT-637</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MDT-637</intervention_name>
    <description>Inhaled doses of MDT-637 over a 10 day period</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and/or surgically sterile or post-menopausal females (confirmed by FSH test);&#xD;
             males must agree to practice barrier contraception until they are discharged from the&#xD;
             study&#xD;
&#xD;
          -  Willing to give written informed consent&#xD;
&#xD;
          -  18 to 50 years of age&#xD;
&#xD;
          -  BMI of 19-30 kg/m2&#xD;
&#xD;
          -  Non-smoker (for at least 90 days prior to screening) and willing to abstain from&#xD;
             smoking during the course of the study&#xD;
&#xD;
          -  Good general health as determined by medical history, physical examination,&#xD;
             spirometry, ECG and clinical laboratory tests&#xD;
&#xD;
          -  Willing to abstain from alcohol, caffeine, and xanthine-containing beverages for 24&#xD;
             hours prior to and 24 hours after dosing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled, clinically significant disease which in the opinion of the Principal&#xD;
             Investigator and Sponsor (MDTx) would place the subject at risk through study&#xD;
             participation or would confound the assessment of the safety of MDT-637&#xD;
&#xD;
          -  Evidence of current or history of respiratory disease; for instance asthma, emphysema,&#xD;
             chronic bronchitis or cystic fibrosis.&#xD;
&#xD;
          -  Upper respiratory tract infection within 6 weeks of Visit 1&#xD;
&#xD;
          -  Symptoms of rhinitis (stuffy nose, rhinorrhea, sneezing, nasal discharge) within 2&#xD;
             weeks of Visit 1&#xD;
&#xD;
          -  Current symptoms of cough, dyspnea, wheezing or nocturnal awakenings due to&#xD;
             respiratory symptoms&#xD;
&#xD;
          -  History of significant nasal irritation from nasal inhalation of medication&#xD;
&#xD;
          -  History of malignancy&#xD;
&#xD;
          -  History of clinically significant alcohol or drug abuse&#xD;
&#xD;
          -  Positive drug screen for drugs of abuse&#xD;
&#xD;
          -  Positive test for HIV, Hepatitis B or Hepatitis C&#xD;
&#xD;
          -  Allergy to lactose, or lactose intolerance&#xD;
&#xD;
          -  Use of prescription medication within 14 days of Visit 2 or over-the-counter&#xD;
             preparations, including dietary and herbal supplements, within 5 days of Visit 2&#xD;
&#xD;
          -  Positive urine pregnancy test at Visit 1&#xD;
&#xD;
          -  Inability to perform reproducible spirometry in accordance with American Thoracic&#xD;
             Society/European Respiratory Society (ATS/ERS) guidelines&#xD;
&#xD;
          -  Abnormal QTc interval at Visit 1(&gt;450 msec in males or &gt; 470 msec in females)&#xD;
&#xD;
          -  Significant blood donation (or testing) in previous 8 weeks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>West Coast Clinical Trials</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://mdtx.com/pipeline/proprietary-products/mdt-637/</url>
    <description>Related Info</description>
  </link>
  <verification_date>April 2012</verification_date>
  <study_first_submitted>December 7, 2011</study_first_submitted>
  <study_first_submitted_qc>December 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2011</study_first_posted>
  <last_update_submitted>April 10, 2012</last_update_submitted>
  <last_update_submitted_qc>April 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Respiratory Syncytial Virus Infection</keyword>
  <keyword>RSV</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

